Will Senseonics (SENS) Stock Surge to $5? This Analyst Says Yes

Canaccord analyst Kyle Rose is out with a research note on shares of Senseonics (NYSE:SENS), after the medical technology company released its second-quarter results, which demonstrated “continued momentum in OUS markets, execution on key US commercial initiatives, and the completion of a successful capital raise that can support the ongoing commercialization of Eversense.”

Rose reiterates a Buy rating on Senseonics shares, with a price target of $5.00, which represents a potential upside of 25% from where the stock is currently trading.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Kyle Rose has a yearly average return of 13.4% and a 54% success rate. Rose has a 15.3% average return when recommending SENS, and is ranked #414 out of 4850 analysts.

The analyst noted, “While Q2 revenues came in slightly below expectations, management raised FY18 revenue guidance given increased confidence in the OUS business and better-than-expected readiness/demand in the US. That said, we’ve reviewed our H2/18 growth metrics and have scrubbed our forward growth assumptions, taking a slightly more conservative tone with respect to the first 18 months of US commercialization. This is not intended as a negative signal to investors – our LT view on the market opportunity and commercial differentiation are unchanged – rather, a sanity check to prevent our assumptions on patient additions/utilization from becoming too ambitious in the early days of US commercialization.”

Senseonics has one of the best ratings by the Street. TipRanks reveals that SENS has a Strong Buy analyst consensus rating with 6 back-to-back buy ratings in the last 12 months. Meanwhile, the average analyst price target of $5.90 suggests the stock still has upside potential of just over 47% from the current share price for the next 12 months.

Senseonics is a medical technology company focused on the development and commercialization of transformational glucose monitoring products designed to help people with diabetes confidently live their lives with ease. 

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts